ZOKINVY

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, United States

Active ingredients

The drug ZOKINVY contains one active pharmaceutical ingredient (API):

1 Lonafarnib UNII IOW153004F - LONAFARNIB

Lonafarnib is a disease modifying agent that prevents farnesylation, thereby reducing the accumulation of aberrant progerin and progerin-like proteins in the cell’s inner nuclear membrane. This results in maintaining cell integrity and normal function. Read about Lonafarnib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZOKINVY Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AX20		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3046788, 3046799
Country: FR	Base de données publique des médicaments	Identifier(s): 61837140, 66601425
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9043, 9044
Country: IT	Agenzia del Farmaco	Identifier(s): 050224017, 050224029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095122, 1095123
Country: US	FDA, National Drug Code	Identifier(s): 73079-050, 73079-075